Clinical significance of the tumour markers CA 125 II and CA 72-4 in ovarian carcinoma

International Journal of Cancer

Volumn 69, Issue 4, 1996, Pages 329-334

  Hasholzner, Ute ^a   Baumgartner, Ludwig ^a   Stieber, Petra ^a   Meier, Werner ^a   Reiter, Wolfgang ^a   Fahl, Heike ^a   Fateh Moghadam, Ahmad ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 72-4 ANTIGEN; TUMOR MARKER;

ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA, MUCINOUS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-125 ANTIGEN; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; OVARIAN NEOPLASMS; REFERENCE VALUES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 0029823113     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960822)69:4<329::AID-IJC16>3.0.CO;2-0     Document Type: Article

References (20)

1. BAST, R.C., JR., KNAUF, S., EPENETOS, A., DHOKIA, A., DALY, L., TANNER, M., SOPER, J., CRESMAN, W., GALL, S. and KNAPP, R.C., Coordinate elevation of scrum markers in ovarian cancer but not in benign disease. Cancer, 68(8), 1758-1763 (1991).
2. BAYERL, B., MEIER, W., STIEBER, P., ALBIEZ, M., EIERMANN, W. and FATEH-MOGHADAM, A., Significance of CA 72-4 in the diagnosis of ovarian cancer. In: R. Klapdor (ed.), Recent results in tumour therapy and diagnosis, pp. 111-112, Zuckschwedt-Verlag Munich (1990).
3. BYRNE, D.J., BROWNING, M.C. and CUSCHIERI, A., CA 72-4: a new tumour marker for gastric cancer. Br. J. Surg., 77(9), 1010-1013 (1990).
4. COLCHER, D., HORAN HAND, P., NUTI, M. and SCHLOM, J.A., Proc. nat. Acad. Sci. (Wash.), 78, 3199 (1981).
5. GERO, E.J., COLCHER, D., FERRONI, O., MELSHEIMER, R., GIANI, S., SCHLOM, J. and KAPLAN, P., CA 72-4 radioimmunoassay for the detection of TAG-72 carcinoma associated antigen in serum of patients. J Clin. Lab. Anal. 3(6), 360-369 (1989).
6. GUADAGNI, F., ROSELLI, M., AMATO, T., COSIMELLI, M., CASALE, V., CARLINI, M., SANTORO, E., CAVALIERE, R. and GREINER, J.W., CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG 72) as a serum marker on the management of gastric carcinoma. Cancer Res., 52, 1222-1227 (1992).
7. GUADAGNI, F., MARTH, C., ZEIMET, A.G., FERRONI, P., SPILA, A., ABBOLITO, R., ROSSELI, M., GREINER, J.W. and SCHLOM, J., Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases. Am. J. Obstet. Gynecol., 171, 1183-1191 (1994).
8. HASHOLZNER, U., BAUMGARTNER, L., STIEBER, P., MEIER, W., HOFMANN, K. and FATEH-MOGHADAM, A., Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma. Anticancer Research, 14, 2743-2746 (1994).
9. KLAPDOR, R., Arbeitsgruppe Qualitätskontrolle und Standardisierung von Tumormarkertests in Rahmen der Hamburger Symposien über Tumormarker, Tumordiagn. Ther., 13, XIX (1992).
10. KENEMANS, P., YEDEMA, C.A., BON, G.G. and VON MENSDORFF-POUILLY, S., CA 125 in gynecological pathology - a review, Europ. J. Obst. Cyn. Rep. Bio., 49, 115-124 (1983).
11. MEIER, W., STIEBER, P., FATEH-MOGHADAM, A., EIERMANN, W. and HEPP, H., CA 125 in gynecological malignancies. Europ. J. Cancer Clin. Oncol., 23, 713 (1987).
12. MEIER, W., STIEBER, P., FATEH-MOGHADAM, A., EIERMANN, W. and HEPP, H., CA 125 Serumwerte und histologischer Befund zum Zeitpunkt der Second-look-Laparotomie beim Ovarialkarzinom. Geburtsh. Frauenheilk.,48, 331 (1988).
13. MURARO, R., KUROKI, M., WUNDERLICH, S., POOLE, D.J., COLCHER, S., THOR, A., GREINER, J.W., SIMPSON, J.F., MOLINOLO, A., NOOUCHI, P. and SCHLOM, J., Generation and characterization of B 72.3 second-generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res., 48, 4588 (1988).
14. NUTI, M., TERAMOTO, Y.A., MARIANI-COSTANTINT, R., HORAN HAND, P., COLCHER, D. and SCHLOM, J., A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in a human mammary carcinoma cell population. Int. J. Cancer, 29, 539 (1982).
15. OHUCHI, N., TAKAHASHI, K., MATOBA, N., SATO, T., TAIRA, Y., SAKAI, N., MASUDA, M. and MORI, S., Comparison of serum assays for TG-72, CA 19-9 and CEA in gastrointestinal carcinoma patients. Jpn. J. Clin. Oncol., 19(3), 242-248 (1989).
16. QUARANTA, M., LORUSSO, V., COVIELLO, M., MICELLI, G. and CASAMASSIMA, A., CA 125 in the monitoring of response to chemotherapy of ovarian carcinoma. Int. J. Cancer, Suppl. 3, 68-70 (1988).
17. REITER, W., STIEBER, P., REUTER, C., HASHOLZNER, U., BAUMGARTNER, L., PAHL, H. and FATEH-MOGHADAM, A., Untersuchungen zur methodischen und klinischen Wertigkeit eines neuen CA 72-4 Enzymimmunoassays. Lab med., 19, 203-209 (19956).
18. REITER, W., STIEBER, P., REUTER, C., NAGEL, p., CRAMER, C. and FATEH-MOGHADAM, A., Sensitivity and prognostic significance of CA 72-4, CEA and CA 19-9 serum levels in untreated patients with gastric cancer. Tumordiagn. Ther., 16, 98-101 (1995a).
19. STIEBER, P., FATEH-MOGHADAM, A., WÄDLICH, H., NAGEL, D., LAMERZ, R. and DENECKE, H., CA 72-4: a new tumor marker in stomach cancer. In: R. Klapdor (ed.), Recent results in tumor diagnosis and therapy, p. 23, Zuckschwerdt-Verlag Munich (1990).
20. VAN DALEN, A., Quality control and standardisation of tumour marker tests, Tumor Biol. 14, 131-135 (1993).